Insmed's DPP1 inhibitor Brinsupri (brensocatib) has been recommended by the CHMP for the treatment of patients aged 12 and ...

If Approved, BRINSUPRI Would Be the First and Only Treatment in the European Union for Non-Cystic Fibrosis Bronchiectasis ...

EMA committee recommends approval of Insmed’s Brinsupri to treat non-cystic fibrosis bronchiectasis: Bridgewater, New Jersey Monday, October 20, 2025, 15:00 Hrs [IST] Insmed Inc ...

Brinsupri is an oral inhibitor of dipeptidyl peptidase 1 and targets neutrophilic serine proteases, which mediate ...

In bronchiectasis, highly symptomatic patients have a greater risk of exacerbations and may benefit from long-term macrolide treatment.

Brensocatib effectively reduces NSP activity in bronchiectasis patients, with greater reductions observed in the 25-mg dose group compared to the 10-mg group.

Inhaled corticosteroids pose long-term risks in COPD management, prompting careful screening and potential de-escalation ...

Bridgewater, New Jersey Saturday, October 18, 2025, 18:00 Hrs [IST] ...

Sanofi (SNY) stock and Insmed (INSM) stock are in focus as new treatments from the companies win backing from an expert panel ...

On October 17, 2025, Insmed announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending approval of BRINSUPRI for non-cystic ...

If you receive a denial letter from your insurer, seek legal advice before appealing the decision, says a leading disability lawyer.

Prior exacerbations and greater symptom severity independently predicted future exacerbations in patients with bronchiectasis. Long-term macrolide proved beneficial not only for patients with frequent ...